News | March 30, 2022
OPPI summit calls for collaboration across stakeholders
The summit also saw the launch of two important reports- Multi-Regional Clinical Trials (MRCT) and Value of OTC in India
The summit also saw the launch of two important reports- Multi-Regional Clinical Trials (MRCT) and Value of OTC in India
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
Approval is based on results of a multicenter, randomized, open-labeled and controlled IDE clinical study that demonstrated the superiority of Agili-C™ implant to the current surgical standard of care, debridement and microfracture in the knee joint
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults
In May 2021, Daiichi Sankyo had submitted a supplemental new drug application (sNDA) for Tarlige tablets based on results from a phase 3 trial in patients with CNP
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Clinical trials for minimally invasive therapy procedures using advanced imaging from Philips Lung Suite start with successful first cases
Vela Analytics can create concise, evidence-based in-house reports that help customers with the information to make timely, informed decisions about possible treatment options
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
Subscribe To Our Newsletter & Stay Updated
